Rizatriptan Benzoate

Treats migraine with or without aura. ANDA 201967, held by Glenmark Pharms Ltd. Rizatriptan Benzoate.

As of Nov 14, 2026, ANDA 201967 (Rizatriptan Benzoate), held by Glenmark Pharms Ltd, was first approved by FDA on Dec 31, 2012, with 1 approved supplement and 0 published complete response letters.

First approved: Dec 31, 2012
Supplements approved: 1
Complete response letters: 0

What It's For

From the FDA-approved label (Indications and Usage)

Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use

Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks.
Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine.

Full prescribing information on DailyMed ↗

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 2 submissions below

Date	Submission	Status	Documents
Dec 31, 2012	Original application	Approved	None posted

Products

2 strengths and forms


Rizatriptan BenzoateEQ 5MG BASE · tablet;oral	Rizatriptan Benzoate	Discontinued
Rizatriptan BenzoateEQ 10MG BASE · tablet;oral	Rizatriptan Benzoate	Discontinued

All 2 submissions, including labeling and manufacturing supplements


Sep 21, 2020	Supplement 3Labeling · Standard review	Approved	None posted
Dec 31, 2012	Original application	Approved	None posted

Identifiers

Application: ANDA 201967
Drugs@FDA: Overview at FDA
Company: Glenmark Pharmaceuticals

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters